Key Message

We found 5 evidence-based guidelines about the treatment of alcohol withdrawal in outpatient settings.

Key Message

We did not find any studies on the clinical effectiveness of vasopressin versus alternative pharmacologic interventions for the management of significant vaginal bleeding following miscarriage.

We did not find any relevant evidence-based guidelines on the use of vasopressin for the management of significant vaginal bleeding following miscarriage.

Key Message

• Continuous glucose monitoring (CGM) is a method of glucose testing in which a sensor is inserted into the skin and continuously monitors interstitial glucose concentrations. Real-time continuous glucose monitoring (rtCGM) systems automatically measure glucose and display a recent glucose value.
• Evidence suggests that rtCGM may improve hemoglobin A1C and time in range in adults and pediatric patients with type 1 diabetes, but this is uncertain.
• Limited evidence suggests that in people with type 1 diabetes, there is little to no difference between rtCGM and self-monitoring of blood glucose (SMBG) on quality of life, diabetic ketoacidosis, and severe adverse events.
• Safety evidence suggests that rtCGM may decrease severe hypoglycemia in adults and pediatric patients with type 1 diabetes, but this is uncertain.
• rtCGM may be more cost-effective in the long term than SMBG in adults with type 1 diabetes.

Key Message

We found 3 evidence-based guidelines regarding pharmaceutical treatment for attention-deficit/hyperactivity disorder.

Key Message

We found 1 randomized controlled trial about the clinical effectiveness of extended-release methylphenidate with an osmotic-controlled release oral delivery system for the treatment of attention-deficit/hyperactivity disorder in adults.

Key Message

• Five evidence-based guidelines met the eligibility criteria for this report. Of the 5 guidelines, 2 provided recommendations on rheumatology practice, 1 on stroke, 1 on oncology, and 1 on digital innovations for all areas of health; none of them focused on primary care specifically. Three were developed in the context of COVID-19.
• While all 5 guidelines were informed by a systematic literature search, some specific recommendations were based on expert consensus, given the absence of literature on the respective topics. The quality of evidence and strength of recommendations, where available, were generally assessed to be low across the guidelines.
• The evidence-based guidelines provided recommendations across various aspects of virtual care delivery including population considerations, patient conditions, and the types of care that can be offered virtually. They also provided recommendations on when to offer or discontinue virtual care, on patient privacy, and on staff training. One guideline provided a recommendation on fees and reimbursement.
• Multiple evidence-based guidelines stated that virtual care should complement rather than replace in-person care, and that virtual care should only be implemented when adequate resources and personnel are available and patient privacy can be secured.

Key Message

Three systematic reviews and 1 randomized controlled trial about the clinical utility of screening for asymptomatic bacteriuria versus no screening in people who are pregnant and are not at risk for bacteriuria were identified.

No literature about the clinical utility of screening for asymptomatic bacteriuria with different screening approaches or algorithms in people who are pregnant and are not at high risk for bacteriuria was identified.

Six evidence-based guidelines about the use of screening for asymptomatic bacteriuria in people who are pregnant and are not at high risk for bacteriuria were identified.

Key Message

Continuous glucose monitoring is a method of glucose testing in which a sensor is inserted into the skin and continuously monitors interstitial glucose concentrations. Real-time continuous glucose monitoring (rtCGM) systems automatically measure glucose and display a recent glucose value. Intermittently scanned continuous glucose monitoring (isCGM) systems require the person using the system to scan the sensor to display glucose information. The evidence of the comparative effectiveness of isCGM versus rtCGM for improving time in range, time above range, A1C, and quality of life in people with type 1 diabetes is uncertain. Evidence from some studies suggested there was a significant benefit favouring rtCGM versus isCGM for these outcomes, whereas other studies found no significant differences between treatment groups. Evidence suggested that people with type 1 diabetes using rtCGM spent significantly less time below range/time in hypoglycemia than those using isCGM. The evidence of the comparative safety of isCGM versus rtCGM in people with type 1 diabetes is limited and uncertain. Evidence from 1 study suggested that severe hypoglycemic events were more frequent in those using isCGM. In other studies, there were no severe hypoglycemic events in either treatment group. No studies were identified that evaluated the comparative effectiveness of isCGM versus rtCGM in people living with type 2 diabetes or gestational diabetes.